Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol- 5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor

Journal of Medicinal Chemistry

Volumn 49, Issue 7, 2006, Pages 2143-2146

  Bhide, Rajeev S ^a   Cai, Zhen Wei ^a   Zhang, Yong Zheng ^a   Qian, Ligang ^a   Wei, Donna ^a   Barbosa, Stephanie ^a   Lombarde, Louis J ^a   Borzilleri, Robert M ^a   Zheng, Xiaoping ^a   Wu, Laurence I ^a   Barrish, Joel C ^a   Kim, Soong Hoon ^a   Leavitt, Kenneth ^a   Mathur, Arvind ^a   Leith, Leslie ^a   Chao, Sam ^a   Wautlet, Barri ^a   Mortillo, Steven ^a   Jeyaseelan Sr , Robert ^a   Kukral, Daniel ^a   Hunt, John T ^a   Kamath, Amrita ^a   Fura, Aberra ^a   Vyas, Viral ^a   Marathe, Punit ^a   D'Arienzo, Celia ^a   Derbin, George ^a   Fargnoli, Joseph ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 (4 FLUORO 2 METHYL 1H INDOL 5 YLOXY) 5 METHYLPYRROLO[2,1 F][1,2,4]TRIAZIN 6 YLOXY]PROPAN 2 OL; ALANINE; ALKYL GROUP; BMS 540215; BMS 582664; FUNCTIONAL GROUP; METHYL GROUP; PRODRUG; PROTEIN TYROSINE KINASE INHIBITOR; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCHEMISTRY; CLINICAL TRIAL; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

ALANINE; ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PRODRUGS; PYRROLES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS; TRIAZINES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 33645670595     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm051106d     Document Type: Article

References (20)

1. (a) Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat. Med. 1995, 1, 27-31.
2. (b) Carmeliet, P.; Jain, R. K. Angiogenesis in cancer and other diseases. Nature 2000, 407, 249-257.
3. Traxler, P. Tyrosine kinases as targets in cancer therapy - successes and failures. Exp. Opin. Ther. Targets 2003, 7, 215.
4. Shawver, L. K.; Lipson, K. E.; Fong, T. A. T.; McMahon, G.; Plowman, G. D.; Strawn, L. M. Receptor tyrosine kinases as targets for inhibition of angiogenesis. Drug Discover Today 1997, 2, 50-63.
5. Ferrara, N.; Gerber, H. P.; Lecouter, J. Nat. Med. 2003, 9, 669
6. (a) Sepp-Lorenzino, L.; Thomas, K. A. Antiangiogenic agents targeting vascular endothelial growth factor and its receptors in clinical development. Exp. Opin. Investig. Drugs 2002, 11, 1447-1465.
7. (b) Bilodeau, M. T.; Fraley, M. E.; Hartman, G. D. Kinase insert domain-containing receptor kinase inhibitors as antiangiogenic agents. Exp. Opin. Invest. Drugs 2002, 11, 737-745.
8. (c) Underiner, T. L.; Ruggeri, B.; Gingrich, D. E. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as antiangiogenic agents in cancer therapy. Curr. Med. Chem. 2004, 11, 731-745.
9. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl. J. Med. 2004, 150, 2335-2342.
10. (a) Wood, J. M.; Bold, G.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Frei, J.; Hofmann, F.; Mestan, J.; Mett, H.; O'Reilly, T.; Persohn, E.; Rösel, J.; Schnell, C.; Stover, D.; Theuer, A.; Towbin, H.; Wenger, F.; Woods-Cook, K.; Menrad, A.; Siemeister, G.; Schirner, M.; Thierauch, K.-H.; Schneider, M. R.; Drevs, J.; Martiny-Baron, G.; Totzke, F.; Marmé. D. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000, 60, 2178-2189.
11. (b) Abrams, T. J.; Murray, L. J.; Pesenti, E.; Walker Holway, V.; Colombo, T.; Lee, L. B.; Cherrington, J. M.; Pryer, N. K. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol. Cancer Ther. 2003, 2, 1011-1021.
12. (c) Hennequin, L. F.; Stokes, E. S. E.; Thomas, A. P.; Johnstone, C.; Plé, P. A.; Ogilvie, D. J.; Dukes, M.; Wedge, S. R.; Kendrew, J.; Curwen, J. O. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J. Med. Chem. 2002, 45, 1300-1312.
13. (d) Beebe, J. S.; Jani, J. P.; Knauth, E.; Goodwin, P.; Higdon, C.; Rossi, A. M.; Emerson, E.; Finkelstein, M.; Floyd, E.; Harriman, S.; Atherton, J.; Hillerman, S.; Soderstrom, C.; Kou, K.; Gant, T.; Noe, M. C.; Foster, B.; Rastinejad, F.; Marx, M. A.; Schaeffer, T.; Whalen, P. M.; Roberts, W. G. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res. 2003, 63, 7301-7309.
14. (e) Gingrich, D. E.; Reddy, D. R.; Iqbal, M. A.; Singh, J.; Aimone, L. D.; Angeles, T. S.; Albom, M.; Yang, S.; Ator, M. A.; Meyer, S. L.; Robinson, C.; Ruggeri, B. A.; Dionne, C. A.; Vaught, J. L.; Mallamo, J. P.; Hudkins, R. L. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)-indeno[2,1-a]pyrrolo[3,4-i-] carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. J. Med. Chem. 2003, 46, 5375-5388.
15. (f) Wedge, S. R.; Kendrew, J.; Hennequin, L. F.; Valentine, P. J.; Barry, S. T.; Brave, S. R.; Smith, N. R.; James, N. H.; Dukes, M.; Curwen, J. O.; Chester, R.; Jackson, J. A.; Boffey, S. J.; Kilburn, L. L.; Barnett, S.; Richmond, G. H. P.; Wadsworth, P. F.; Walker, M.; Bigley, A. L.; Taylor, S. T.; Cooper, L.; Beck, S.; Jurgensmeier, J. M.; Ogilvie, D. J. AZD2171: A highly potent, orally bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the treatment of Cancer. Cancer Res. 2005, 65, 4389-4400.
16. Borzilleri, R. M.; Fargnoli, J.; Fura, A.; Gerhardt, T.; Hunt, J. T.; Mortillo, S.; Qian, L.; Tokarski, J.; Vyas, V.; Wautlet, B.; Zheng, X.; Bhide, R. S. Synthesis and SAR of 4-(3-hydroxyphenylamino)-pyrrolo[2,1-f][1,2,4] triaxine based VEGFR-2 kinase inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 1429.
17. Borzilleri, R. M.; Zheng, X.; Qian, L.; Ellis, C.; Cai, Z.-W.; Wautlet, B.; Mortillo, S.; Jeyaseelan, R.; Kukral, D. W.; Fura, A.; Kamath, A.; Vyas, V.; Tokarski, J. S.; Barrish, J. C.; Hunt, J. T.; Lombarde, L. J.; Fargnoli, J.; Bhide, R. S. J. Med. Chem. 2005, 48, 3991-4008.
18. (a) Bhide, R. S.; Fan, J.; Parlanti, L.; Barbosa, S.; Qian, L.; Cai, Z.-W.; Gibson, F. S. Process for preparing certain pyrrolotriazine compounds. PCT Int. Appl. WO 2004009542.
19. (b) Hennequin, L.; Stokes, E.; McKerrecher, D. Quinazoline derivatives as angiogenesis inhibitors. PCT Int. Appl. WO 200047212.
20. For the assay conditions of in vitro kinase, cellular proliferation, metabolic stability, cytochrome P450, and pharmacokinetic parameters, see ref 9.